President and CEO of Avanir Pharmaceuticals (AVNR, Financial) Keith Katkin sells 35,025 shares of AVNR on 01/05/2010 at an average price of $1.92 a share.
AVANIR Pharmaceuticals is focused on developing, acquiring and commercializing novel therapeutic products for the treatment of chronic diseases. AVANIR's products and product candidates address therapeutic markets that include the central nervous system, cardiovascular disorders, inflammation and infectious diseases. AVANIR currently markets FazaClo, the only orally-disintegrating formulation of clozapine for the management of severely ill schizophrenic patients who fail to respond adequately to standard drug treatments for schizophrenia. FazaClo is also indicated for reducing the risk of suicidal behavior in patients with schizophrenia or schizoaffective disorder. AVANIR has an ongoing development program with Novartis International Pharmaceutical Ltd. for the treatment of inflammatory disease. The Company's first commercialized product, Abreva, is marketed in North America by GlaxoSmithKline Consumer Healthcare and is the leading over-the-counter product for the treatment of Avanir Pharmaceuticals has a market cap of $158.1 million; its shares were traded at around $1.9 with and P/S ratio of 37.6.
AVANIR Pharmaceuticals is focused on developing, acquiring and commercializing novel therapeutic products for the treatment of chronic diseases. AVANIR's products and product candidates address therapeutic markets that include the central nervous system, cardiovascular disorders, inflammation and infectious diseases. AVANIR currently markets FazaClo, the only orally-disintegrating formulation of clozapine for the management of severely ill schizophrenic patients who fail to respond adequately to standard drug treatments for schizophrenia. FazaClo is also indicated for reducing the risk of suicidal behavior in patients with schizophrenia or schizoaffective disorder. AVANIR has an ongoing development program with Novartis International Pharmaceutical Ltd. for the treatment of inflammatory disease. The Company's first commercialized product, Abreva, is marketed in North America by GlaxoSmithKline Consumer Healthcare and is the leading over-the-counter product for the treatment of Avanir Pharmaceuticals has a market cap of $158.1 million; its shares were traded at around $1.9 with and P/S ratio of 37.6.
CEO Recent Trades:
- Sell:: President and CEO Keith Katkin sold 37,335 shares of AVNR stock on 12/15/2009 at the average price of 1.82, the price of the stock has increased by 4.4% since.
Directors and Officers Recent Trades:
- Sell:: 10% Owner Jay Moorin sold 1,778,992 shares of AVNR stock on 10/13/2009 at the average price of 2.31, the price of the stock has decreased by 17.75% since.
- Sell:: Sr. VP, Chief Medical Officer Randall Kaye sold 2,000 shares of AVNR stock on 09/15/2009 at the average price of 2.1, the price of the stock has decreased by 9.52% since.
- Sell:: 10% Owner Ventures Fund Vi, L.p. Vivo sold 411,366 shares of AVNR stock on 07/31/2009 at the average price of 2.33, the price of the stock has decreased by 18.45% since.
